ARCUTIS BIOTHERAPEUTICS INC
ARQTNASDAQ🏆 #1524 by market capEarnings Oct 27US Equity
$26.21▼ $0.02 (−0.07%)
Live1h▲ 0.0%
24h▼ 0.1%
7d▼ 2.9%
14d▼ 6.0%
30d▼ 3.4%
1y▲ 77.7%
🏦Market Cap
$3.28B
Small Cap
📈Revenue Growth (YoY)
+76.1%
High Growth
📊Gross Margin
91.1%
High
💵FCF Margin
—
⚖️P/S Ratio
7.0x
Fair
Otter Score
55
Weak
📊
Analyst Ratings
Price
$26.21
Total
12
Raised
0
Lowered
1
Avg PT
$36.67
H / L
$38 / $34
| Institution | Action | Rating | Date |
|---|---|---|---|
Needham | Reiterated | Buy | 2026-05-07 |
Mizuho | Reiterated | Outperform | 2026-03-02 |
Guggenheim | Reiterated | Buy | 2026-02-27 |
HC Wainwright & Co. | Reiterated | Buy | 2026-02-26 |
TD Cowen | Reiterated | Buy | 2026-02-26 |
Goldman Sachs | Reiterated | Neutral | 2025-10-30 |
Jefferies | Reiterated | Buy | 2025-03-11 |
Morgan Stanley | Reiterated | Overweight | 2023-11-13 |
JonesTrading | Downgraded | Buy → Hold | 2023-11-08 |
Cantor Fitzgerald | Reiterated | Overweight | 2023-08-22 |
Truist Securities | Reiterated | Buy | 2023-05-26 |
Cowen & Co. | Reiterated | Outperform | 2021-02-01 |
One row per institution, most recent rating